| Anemia and heart failure. | |
| | |
MedLine Citation:
|
PMID: 16036042 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Over the past few years, anemia has emerged as a powerful independent predictor of adverse outcomes in chronic heart failure (CHF). It affects up to 50% of patients with CHF, depending on the definition of anemia used and on the population studied. Even small reductions in hemoglobin are associated with worse outcome. However, the causes of anemia in CHF remain unclear, although impairment of renal function and inflammatory cytokines are proposed mechanisms. Both may act through impairment of the synthesis or action of erythropoietin. Preliminary studies have demonstrated improvement in symptoms, exercise tolerance, quality of life, and reductions in hospitalizations when patients with severe CHF were treated with erythropoietin. The benefits and the potential risks of such therapies will be further addressed in upcoming larger randomized trials. The recent interest in anemia reflects a new perspective in heart failure therapy, focusing on non-cardiovascular comorbidities. |
| | |
Authors:
|
Eileen O'Meara; Clare Murphy; John J V McMurray |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current heart failure reports Volume: 1 ISSN: 1546-9530 ISO Abbreviation: Curr Heart Fail Rep Publication Date: 2004 Dec |
Date Detail:
|
Created Date: 2005-07-22 Completed Date: 2005-10-07 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 101196487 Medline TA: Curr Heart Fail Rep Country: United States |
Other Details:
|
Languages: eng Pagination: 176-82 Citation Subset: IM |
Affiliation:
|
Department of Cardiology, Western Infirmary, Glasgow G11 6NT, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Anemia / drug therapy, epidemiology*, etiology, physiopathology Anemia, Iron-Deficiency / epidemiology Angiotensin-Converting Enzyme Inhibitors / pharmacology Cytokines / pharmacology Erythropoietin / blood, therapeutic use Female Heart Failure / blood, epidemiology*, physiopathology Hemodilution Humans Kidney Failure, Chronic / epidemiology Male Prevalence Prognosis Receptors, Angiotensin / antagonists & inhibitors Risk Factors |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin-Converting Enzyme Inhibitors; 0/Cytokines; 0/Receptors, Angiotensin; 11096-26-7/Erythropoietin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Aldosterone in heart failure: pathophysiology and treatment.
Next Document: Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension.